Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LCR008
MIFTS: 43

Lacrimal Apparatus Disease

Categories: Eye diseases
Genes Tissues Related diseases Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lacrimal Apparatus Disease

About this section

MalaCards integrated aliases for Lacrimal Apparatus Disease:

Name: Lacrimal Apparatus Disease 12 15 17
Lacrimal Apparatus Diseases 74

Classifications:

MalaCards categories:
Anatomical: Eye diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:1400
ICD9CM 36 375 375.9
MeSH 45 D007766
NCIt 51 C26809
SNOMED-CT 69 31053003
ICD10 34 H04 H04.9
UMLS 74 C0022904
Sources

Summaries for Lacrimal Apparatus Disease

About this section
MalaCards based summary : Lacrimal Apparatus Disease, also known as lacrimal apparatus diseases, is related to excessive tearing and staphylococcal toxic shock syndrome, and has symptoms including visual disturbance, eye manifestations and dacryops. An important gene associated with Lacrimal Apparatus Disease is DCXR (Dicarbonyl And L-Xylulose Reductase), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Hyaluronic acid and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and bone, and related phenotype is digestive/alimentary.

Sources

Related Diseases for Lacrimal Apparatus Disease

About this section

Diseases related to Lacrimal Apparatus Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Related Disease Score Top Affiliating Genes
1 excessive tearing 11.5
2 staphylococcal toxic shock syndrome 10.6 IL1B TNF
3 subacute cutaneous lupus erythematosus 10.6 TNF TRIM21
4 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL6 TNF
5 critical limb ischemia 10.5 IL6 TNF
6 juvenile ankylosing spondylitis 10.5 IL6 TNF
7 autoimmune myocarditis 10.5 IL6 TNF
8 cardiogenic shock 10.5 IL6 TNF
9 streptococcal toxic-shock syndrome 10.5 IL6 TNF
10 periodontitis, chronic 10.5 IL1B IL6
11 bagassosis 10.5 IL1B IL6
12 tungiasis 10.5 IL10 TNF
13 multifocal choroiditis 10.5 IL10 TNF
14 eye lymphoma 10.5 IL10 IL6
15 diabetic foot ulcers 10.4 IL6 MMP9
16 exudative glomerulonephritis 10.4 IL1B TNF
17 punctate inner choroidopathy 10.4 IL10 TNF
18 acquired metabolic disease 10.4 IL1B IL6 TNF
19 scorpion envenomation 10.4 IL6 TNF
20 palladium allergic contact dermatitis 10.4 IL10 IL17A
21 glossitis 10.4 IL1B IL6 TNF
22 leishmaniasis 10.4 IL10 IL1B TNF
23 laryngitis 10.4 IL1B IL6 TNF
24 tropical endomyocardial fibrosis 10.4 IL10 TNF
25 acute vascular insufficiency of intestine 10.4 IL1B IL6 TNF
26 osteosclerotic myeloma 10.4 IL1B IL6 TNF
27 endomyocardial fibrosis 10.4 IL10 TNF
28 poems syndrome 10.4 IL1B IL6 TNF
29 periapical periodontitis 10.4 IL1B IL6 TNF
30 stachybotrys chartarum 10.4 IL1B IL6 TNF
31 endometrial disease 10.4 IL1B IL6 TNF
32 endometritis 10.4 IL1B IL6 TNF
33 pulpitis 10.4 IL1B IL6 TNF
34 adult-onset still's disease 10.4 IL1B IL6 TNF
35 perinatal necrotizing enterocolitis 10.4 IL1B IL6 TNF
36 dengue shock syndrome 10.4 IL1B IL6 TNF
37 acute respiratory distress syndrome 10.4 IL1B IL6 TNF
38 chikungunya 10.4 IL1B IL6 TNF
39 exanthem 10.4 IL6 TNF TRIM21
40 bacterial vaginosis 10.4 IL1B IL6 TNF
41 myelitis 10.3 IL17A IL6 TNF
42 funisitis 10.3 IL10 IL1B IL6
43 pericarditis 10.3 IL1B IL6 TNF
44 aseptic meningitis 10.3 IL10 IL1B TNF
45 scrub typhus 10.3 IL10 IL1B TNF
46 typhoid fever 10.3 IL1B IL6 TNF
47 intermediate uveitis 10.3 IL10 IL6 TNF
48 post-transplant lymphoproliferative disease 10.3 IL10 IL6 TNF
49 gastrointestinal system cancer 10.3 IL6 MMP9 TNF
50 tonsillitis 10.3 IL1B IL6 TNF

Graphical network of the top 20 diseases related to Lacrimal Apparatus Disease:



Diseases related to Lacrimal Apparatus Disease
Sources

Symptoms & Phenotypes for Lacrimal Apparatus Disease

About this section

UMLS symptoms related to Lacrimal Apparatus Disease:


visual disturbance, eye manifestations, dacryops

MGI Mouse Phenotypes related to Lacrimal Apparatus Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.17 AQP5 IL10 IL17A IL6 MMP9 MUC5AC
Sources

Drugs & Therapeutics for Lacrimal Apparatus Disease

About this section

Drugs for Lacrimal Apparatus Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 324)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
5
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
6
Tocopherol Approved, Investigational Phase 4,Not Applicable 1406-66-2 14986
7
Povidone Approved Phase 4,Not Applicable 9003-39-8
8
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 9865442 444025
9
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 56-81-5 753
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
12
Fluorometholone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 426-13-1 9878
13
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable 50-23-7 5754
14
Hydrocortisone acetate Approved, Vet_approved Phase 4,Not Applicable 50-03-3
15
Lifitegrast Approved Phase 4,Phase 3,Phase 2,Not Applicable 1025967-78-5
16
Azithromycin Approved Phase 4 83905-01-5 447043 55185
17
Ketorolac Approved Phase 4,Phase 2 74103-06-3, 66635-83-4 3826
18
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
19
Sorbitol Approved Phase 4,Not Applicable 50-70-4 5780
20
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68-04-2
21 sodium fluoride Approved Phase 4,Not Applicable 7681-49-4
22
Allantoin Approved Phase 4,Not Applicable 97-59-6 204
23
Menthol Approved Phase 4 2216-51-5 16666
24
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051
25
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
26
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
27
Dipivefrin Approved Phase 4,Phase 3,Phase 1 52365-63-6 3105
28
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
29
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
30
Ofloxacin Approved Phase 4 82419-36-1 4583
31
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
32
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
33
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
34
Tacrolimus Approved, Investigational Phase 4,Phase 3,Not Applicable 104987-11-3 6473866 445643 439492
35
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 5910
36
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
37
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 7440-70-2 271
38
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
39
Vitamin D3 Approved, Nutraceutical Phase 4,Not Applicable 67-97-0 5280795 6221
40
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-02-9 14985
41
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
42
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4,Phase 2 53-43-0 9860744
43
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Not Applicable 8001-79-4
44
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 444795 5538
45
Betaine Approved, Nutraceutical Phase 4,Not Applicable 107-43-7 247
46
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
47 Gallopamil Investigational Phase 4 16662-47-8
48 Tocotrienol Investigational Phase 4,Not Applicable 6829-55-6
49 Rebamipide Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90098-04-7
50
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2 91714-94-2 60726

Interventional clinical trials:

(show top 50) (show all 682)
# Name Status NCT ID Phase Drugs
1 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity Unknown status NCT02992535 Phase 4
2 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
3 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
4 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
5 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
6 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
7 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
8 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
9 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
10 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
11 The Safety and Efficacy of Lacrimal Silicone Intubation for the Management of Epiphora Completed NCT01010659 Phase 4
12 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
13 A Phase 4 Study Investigating the Efficacy of Retaineâ„¢ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaineâ„¢
14 Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms Completed NCT03451396 Phase 4 Lifitegrast
15 The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED Completed NCT02120079 Phase 4 Lotemax;Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
16 A Safety and Efficacy Study of OPTIVE FUSIONâ„¢ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
17 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
18 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
19 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
20 Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase Completed NCT00520260 Phase 4 bromfenac;ketorolac
21 Tear Lipid Layer Thickness With Emollient Eye Drops Completed NCT03380624 Phase 4 Refresh Optive;Refresh Optimum OMEGA 3
22 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops Completed NCT02758327 Phase 4 TheraTears Lubricating Eye Drops
23 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® Completed NCT02554981 Phase 4 Cyclosporine 0.05% Ophthalmic Emulsion
24 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4 cyclosporine 0.05% ophthalmic emulsion;carboxymethylcellulose-based lubricant eye drops
25 Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Completed NCT01970917 Phase 4
26 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
27 Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Completed NCT01198782 Phase 4
28 Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery Completed NCT00909324 Phase 4 Pre-LASIK 0.3% hypromellose;Post-LASIK 0.3% hypromellose
29 Systane Clinical Experience Study Completed NCT00818909 Phase 4
30 Efficacy and Acceptability of Two Lubricant Eye Drops Completed NCT00756678 Phase 4 Lubricant Eye Drops (Optiveâ„¢);Lubricating Eye Drops (blink® Tears)
31 Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV) Completed NCT03223909 Phase 4 PRO-087;Systane Ultra;Systane Ultra Preservative Free
32 Refractive Surgery and Optive Compatibility Study Completed NCT00469157 Phase 4 Optive
33 Soothe Versus Refresh Completed NCT00284999 Phase 4 Soothe;Refresh Tears
34 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
35 The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome Completed NCT03666884 Phase 4 COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
36 Comparison Between Rebamipide 2% Versus Autologous Serum Completed NCT03608761 Phase 4 Rebamipide
37 Quality of Life and Sjögren Syndrome Completed NCT03578900 Phase 4 Xeros;Citric Acid based Mouthwash
38 Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Completed NCT03540823 Phase 4
39 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
40 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
41 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
42 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
43 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
44 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
45 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4 Sodium Carboxymethylcellulose;Levofloxacin;Prednisolone
46 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
47 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
48 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
49 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
50 Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4

Search NIH Clinical Center for Lacrimal Apparatus Disease

Sources

Genetic Tests for Lacrimal Apparatus Disease

About this section
Sources

Anatomical Context for Lacrimal Apparatus Disease

About this section

MalaCards organs/tissues related to Lacrimal Apparatus Disease:

42
Eye, Salivary Gland, Bone, Heart, Testes, Thyroid, B Cells
Sources

Publications for Lacrimal Apparatus Disease

About this section
Sources

Variations for Lacrimal Apparatus Disease

About this section
Sources

Expression for Lacrimal Apparatus Disease

About this section
Search GEO for disease gene expression data for Lacrimal Apparatus Disease.
Sources

Pathways for Lacrimal Apparatus Disease

About this section

Pathways related to Lacrimal Apparatus Disease according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14 BPIFA2 CCR6 DNASE1L1 IL10 IL17A IL1B
2
Cytokine Signaling in Immune system 67
Show member pathways
 13.32 IL10 IL17A IL1B IL6 MMP9 TNF
3
Th17 cell differentiation 38
Show member pathways
 12.56 IL10 IL17A IL1B IL6 TNF
4
Immune response IL-23 signaling pathway 23
Show member pathways
 12.55 IL10 IL17A IL1B IL6 TNF
5
T cell receptor signaling pathway 38
Show member pathways
 12.52 IL10 IL17A IL1B IL6 TNF
6
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.23 IL10 IL17A IL1B IL6 TNF
7
Tuberculosis 38
12.21 IL10 IL1B IL6 TNF
8
IL-1 Family Signaling Pathways 66
Show member pathways
 12.2 IL1B IL6 MUC5AC TNF
9
C-type lectin receptor signaling pathway 38
Show member pathways
 12.19 IL10 IL1B IL6 TNF
10
IL-17 Family Signaling Pathways 66
Show member pathways
 12.18 IL17A IL1B IL6 MMP9 MUC5AC TNF
11
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.15 IL10 IL1B IL6 TNF
12
Microglia Activation During Neuroinflammation: Overview 66
Show member pathways
 12.01 IL1B IL6 MMP9 TNF
13
Spinal Cord Injury 1
11.99 IL1B IL6 MMP9 TNF
14
Th1 Differentiation Pathway 66
Show member pathways
 11.97 IL10 IL17A IL1B IL6 TNF
15
TNF signaling pathway 38
11.93 IL1B IL6 MMP9 TNF
16
Amoebiasis 38
11.86 IL10 IL1B IL6 TNF
17
AGE-RAGE signaling pathway in diabetic complications 38
11.85 IL1B IL6 TNF
18
Hematopoietic cell lineage 38
11.84 IL1B IL6 TNF
19
Rheumatoid arthritis 38
11.83 IL17A IL1B IL6 TNF
20
Pertussis 38
11.74 IL10 IL1B IL6 TNF
21
Dendritic Cells Developmental Lineage Pathway 66
11.72 IL10 IL1B IL6 TNF
22
Lung fibrosis 1
11.62 IL1B IL6 MMP9 TNF
23
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.61 IL1B IL6 MMP9 TNF
24
Legionellosis 38
11.57 IL1B IL6 TNF
25
amb2 Integrin signaling 1
11.5 IL6 MMP9 TNF
26
Interleukin-10 signaling 67
11.49 IL10 IL1B IL6 TNF
27
Interleukin-4 and 13 signaling 67
11.49 IL10 IL17A IL1B IL6 MMP9 TNF
28
Malaria 38
11.47 IL10 IL1B IL6 TNF
29
Transcription_Role of VDR in regulation of genes involved in osteoporosis 23
11.46 IL1B IL6 TNF
30
Innate Lymphoid Cell Differentiation Pathways 66
11.46 CCR6 IL10 IL17A IL1B TNF
31
African trypanosomiasis 38
11.3 IL10 IL1B IL6 TNF
32
Antifolate resistance 38
11.27 IL1B IL6 TNF
33
IL-10 Pathway 65
11.25 IL10 IL1B IL6 TNF
34
G-protein signaling_RhoB regulation pathway 23
11.16 IL10 IL17A IL1B IL6 TNF
35
Development and heterogeneity of the ILC family 1
11.13 IL17A IL1B IL6 TNF
36
Cytokines and Inflammatory Response 1
11.02 IL10 IL1B IL6 TNF
37
G-protein signaling_Rap2B regulation pathway 23
10.97 IL10 IL17A IL1B IL6 TNF
38
Microglia Activation During Neuroinflammation: Microglia Polarization 66
10.95 IL10 IL17A IL1B IL6 MMP9 TNF
Sources

GO Terms for Lacrimal Apparatus Disease

About this section

Cellular components related to Lacrimal Apparatus Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 IL10 IL17A IL1B IL6 LACRT LCN1
2 extracellular region GO:0005576 9.44 BPIFA2 DNASE1L1 IL10 IL17A IL1B IL6

Biological processes related to Lacrimal Apparatus Disease according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.97 IL10 IL17A IL1B IL6 TNF
2 immune response GO:0006955 9.93 CCR6 IL10 IL17A IL1B IL6 TNF
3 defense response to bacterium GO:0042742 9.92 BPIFA2 IL10 LACRT TNF
4 regulation of signaling receptor activity GO:0010469 9.88 IL10 IL17A IL1B IL6 LACRT TNF
5 cellular response to lipopolysaccharide GO:0071222 9.86 IL10 IL1B IL6 TNF
6 positive regulation of interleukin-6 production GO:0032755 9.77 IL1B IL6 TNF
7 humoral immune response GO:0006959 9.76 CCR6 IL6 TNF
8 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.72 IL10 MMP9 TNF
9 negative regulation of growth of symbiont in host GO:0044130 9.63 IL10 TNF
10 cytokine-mediated signaling pathway GO:0019221 9.63 IL10 IL17A IL1B IL6 MMP9 TNF
11 negative regulation of lipid storage GO:0010888 9.62 IL6 TNF
12 endothelial cell apoptotic process GO:0072577 9.61 IL10 TNF
13 positive regulation of chemokine biosynthetic process GO:0045080 9.61 IL1B TNF
14 negative regulation of neurogenesis GO:0050768 9.61 IL1B IL6 TNF
15 regulation of establishment of endothelial barrier GO:1903140 9.59 IL1B TNF
16 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 IL10 TNF
17 positive regulation of fever generation GO:0031622 9.54 IL1B TNF
18 positive regulation of glial cell proliferation GO:0060252 9.54 IL1B IL6 TNF
19 sequestering of triglyceride GO:0030730 9.51 IL1B TNF
20 response to glucocorticoid GO:0051384 9.5 IL10 IL6 TNF
21 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IL1B TNF
22 receptor biosynthetic process GO:0032800 9.48 IL10 TNF
23 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.43 IL10 IL1B TNF
24 positive regulation of DNA-binding transcription factor activity GO:0051091 9.35 IL10 IL1B IL6 TNF TRIM21
25 chronic inflammatory response to antigenic stimulus GO:0002439 9.22 TNF
26 positive regulation of neuroinflammatory response GO:0150078 8.8 IL1B IL6 TNF
27 negative regulation of apoptotic process GO:0043066 10.03 AATF IL10 IL6 LACRT MMP9

Molecular functions related to Lacrimal Apparatus Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 IL10 IL17A IL1B IL6 TNF
Sources

Sources for Lacrimal Apparatus Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....